Efficacy and safety of lenvatinib for patients with advanced or recurrent thymic carcinoma: A real-world retrospective study

Efficacy and safety of lenvatinib for patients with advanced or recurrent thymic carcinoma: A real-world retrospective study - Efficacy and safety of lenvatinib for patients with advanced or recurrent thymic carcinoma: A real-world retrospective study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051645

Enrollment

Registered

2023-07-19

Start date

2023-04-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable advanced or recurrent thymic carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The subjects in this study are consecutive cases that meet all of the following criteria. 1. Patients pathologically diagnosed with thymic carcinoma 2. Patients aged 18 or over 3. Patients with any of the following a, b a. Patients with unresectable thymic carcinoma diagnosed with stage III or IV by Masaoka-Koga classification b. Patients with reccurent thymic carcinoma without indication for curative treatment 4. Patients started on lenvatinib from March 23, 2021 through October 31, 2022

Exclusion criteria

Exclusion criteria: Patients who have expressed their refusal to participate in this study through an information disclosure document

Design outcomes

Primary

Measure	Time frame
The objective response rate in second or later-line treatment	—

Secondary

Measure	Time frame
The objective response rate in first-line treatment Disease control rate Progression-free survival Time to treatment failure Overall survival Safety Course of treatment, including dosage adjustment Efficacy and safety of lenvatinib for ineligible patients in the REMORA study and elderly patients	—

Countries

Japan

Contacts

Public ContactKento Takagi

Graduate School of Medicine, Chiba University Department of respirology

kent.takagi@chiba-u.jp043-222-7171

Outcome results